공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

표면단백질 gp120 : 파이프라인 리뷰

Surface Protein gp120 - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 08월 상품 코드 372683
페이지 정보 영문 75 Pages
가격
US $ 3,500 ₩ 4,037,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,074,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,111,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


표면단백질 gp120 : 파이프라인 리뷰 Surface Protein gp120 - Pipeline Review, H2 2016
발행일 : 2016년 08월 페이지 정보 : 영문 75 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

표면단백질 gp120(Surface Protein gp120)을 표적으로 한 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

표면단백질 gp120 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

  • 단독치료 제품(Monotherapy Products)/병용요법 제품(Combination Products)별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • GlaxoSmithKline Plc
  • Osel, Inc.
  • Sanofi Pasteur SA
  • TeneoBio Inc
  • United Biomedical, Inc.
  • ViiV Healthcare Limited

약제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 16.10.24

Summary:

Global Markets Direct's, 'Surface Protein gp120 - Pipeline Review, H2 2016', provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
  • The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Surface Protein gp120
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Surface Protein gp120 Overview
  • Therapeutics Development
    • Surface Protein gp120 - Products under Development by Stage of Development
    • Surface Protein gp120 - Products under Development by Therapy Area
    • Surface Protein gp120 - Products under Development by Indication
  • Surface Protein gp120 - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Surface Protein gp120 - Products under Development by Companies
  • Surface Protein gp120 - Products under Development by Universities/Institutes
  • Surface Protein gp120 - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Surface Protein gp120 - Companies Involved in Therapeutics Development
    • GlaxoSmithKline Plc
    • Osel, Inc.
    • Sanofi Pasteur SA
    • TeneoBio Inc
    • United Biomedical, Inc.
    • ViiV Healthcare Limited
  • Surface Protein gp120 - Drug Profiles
    • Abzentek - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AIDSVAX B/B + ALVAC-HIV vCP1521 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-585248 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fostemsavir tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV [strains C1086 + TV1] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV-1 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HNG-156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-48U1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit GP120 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Inhibit gp120 for HIV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target gp120 for HIV-1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCP-2438 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VRC-01LS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Surface Protein gp120 - Dormant Projects
  • Surface Protein gp120 - Discontinued Products
    • Surface Protein gp120 - Featured News & Press Releases
      • May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa
      • Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
      • Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches $3 Million Fund for New Therapeutic HIV Vaccine Trial
      • Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
      • Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate
      • Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation
      • Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology
      • Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV
      • Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients
      • May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand
      • Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by Osel, Inc., H2 2016
  • Pipeline by Sanofi Pasteur SA, H2 2016
  • Pipeline by TeneoBio Inc, H2 2016
  • Pipeline by United Biomedical, Inc., H2 2016
  • Pipeline by ViiV Healthcare Limited, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q